News coverage about Akers Biosciences (NASDAQ:AKER) has been trending somewhat positive this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akers Biosciences earned a daily sentiment score of 0.17 on AlphaOne’s scale. AlphaOne also gave news articles about the medical instruments supplier an impact score of 25 out of 100, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the immediate future.
Akers Biosciences (NASDAQ:AKER) traded up 4.412% during mid-day trading on Friday, reaching $1.775. 56,485 shares of the company traded hands. Akers Biosciences has a 12-month low of $1.15 and a 12-month high of $3.70. The company’s 50-day moving average is $1.51 and its 200-day moving average is $1.93. The stock’s market capitalization is $15.71 million.
WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/04/21/akers-biosciences-aker-receiving-somewhat-positive-press-coverage-analysis-finds-updated.html.
Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.